Share-based Payment Arrangement, Expense of Applied Therapeutics, Inc. from 31 Mar 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Applied Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2018 to 30 Sep 2025.
  • Applied Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,141,000, a 45% decline year-over-year.
  • Applied Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $13,935,000, a 74% increase year-over-year.
  • Applied Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $15,567,000, a 112% increase from 2023.
  • Applied Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $7,360,000, a 23% decline from 2022.
  • Applied Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $9,603,000, a 14% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Applied Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $13,935,000 $1,141,000 -$950,000 -45% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $14,885,000 $2,100,000 +$210,000 +11% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $14,675,000 $1,487,000 -$892,000 -37% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $15,567,000 $9,207,000 +$7,581,000 +466% 01 Oct 2024 31 Dec 2024 10-K 15 Apr 2025 2024 FY
Q3 2024 $7,986,000 $2,091,000 +$255,000 +14% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $7,731,000 $1,890,000 +$47,000 +2.6% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $7,684,000 $2,379,000 +$324,000 +16% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $7,360,000 $1,626,000 -$813,000 -33% 01 Oct 2023 31 Dec 2023 10-K 15 Apr 2025 2024 FY
Q3 2023 $8,173,000 $1,836,000 -$1,020,000 -36% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $9,193,000 $1,843,000 -$388,000 -17% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $9,581,000 $2,055,000 -$22,000 -1.1% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $9,603,000 $2,439,000 -$410,000 -14% 01 Oct 2022 31 Dec 2022 10-K 06 Mar 2024 2023 FY
Q3 2022 $10,013,000 $2,856,000 +$211,000 +8% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $9,802,000 $2,231,000 -$471,000 -17% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $10,273,000 $2,077,000 -$904,000 -30% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $11,177,000 $2,849,000 +$130,000 +4.8% 01 Oct 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
Q3 2021 $11,047,000 $2,645,000 +$242,000 +10% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $10,805,000 $2,702,000 +$1,129,000 +72% 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2022 2022 Q2
Q1 2021 $9,676,000 $2,981,000 +$1,650,000 +124% 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $8,026,000 $2,719,000 +$1,371,000 +102% 01 Oct 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
Q3 2020 $6,655,000 $2,403,000 +$1,183,000 +97% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $5,472,000 $1,573,000 -$1,705,000 -52% 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $7,177,000 $1,331,000 +$1,006,000 +310% 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021 2021 Q1
Q4 2019 $6,171,000 $1,348,000 +$1,256,000 +1365% 01 Oct 2019 31 Dec 2019 10-K 18 Mar 2021 2020 FY
Q3 2019 $4,915,000 $1,220,000 +$1,142,000 +1464% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $3,773,000 $3,278,000 +$3,202,000 +4213% 01 Apr 2019 30 Jun 2019 10-Q 11 Aug 2020 2020 Q2
Q1 2019 $571,000 $325,000 +$299,000 +1150% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q4 2018 $272,000 $92,000 01 Oct 2018 31 Dec 2018 10-K 13 Mar 2020 2019 FY
Q3 2018 $78,000 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2019 2019 Q3
Q2 2018 $76,000 01 Apr 2018 30 Jun 2018 10-Q 12 Aug 2019 2019 Q2
Q1 2018 $26,000 01 Jan 2018 31 Mar 2018 10-Q 21 Jun 2019 2019 Q1

Applied Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $15,567,000 +$8,207,000 +112% 01 Jan 2024 31 Dec 2024 10-K 15 Apr 2025 2024 FY
2023 $7,360,000 -$2,243,000 -23% 01 Jan 2023 31 Dec 2023 10-K 15 Apr 2025 2024 FY
2022 $9,603,000 -$1,574,000 -14% 01 Jan 2022 31 Dec 2022 10-K 06 Mar 2024 2023 FY
2021 $11,177,000 +$3,151,000 +39% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
2020 $8,026,000 +$1,855,000 +30% 01 Jan 2020 31 Dec 2020 10-K 10 Mar 2022 2021 FY
2019 $6,171,000 +$5,899,000 +2169% 01 Jan 2019 31 Dec 2019 10-K 18 Mar 2021 2020 FY
2018 $272,000 01 Jan 2018 31 Dec 2018 10-K 13 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.